COMMUNIQUÉS West-GlobeNewswire

Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter

07/11/2024 - 23:00

World’s First Enhanced Small Particle (ESP™) Detection Sorter Enables Effective Content Isolation; Opens Door to Scientific Discoveries FREMONT, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq [...]

Clover Health Reports Strong Third Quarter 2024 Financial Results; Highlights Differentiated Market Opportunity to Grow Membership

06/11/2024 - 22:05

Delivers 9% Total Revenue growth year-to-date compared to prior year period Company improves 2024 year-to-date GAAP Net Loss from Continuing Operations by $117.4 million year-over-year and year-to-date Adjusted EBITDA [...]

Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences

06/11/2024 - 22:05

FOSTER CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product [...]

Option Care Health to Participate in Upcoming Investor Conferences

06/11/2024 - 22:05

BANNOCKBURN, Ill., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, will [...]

Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference

06/11/2024 - 22:05

IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat [...]

Emergent BioSolutions Reports Third Quarter 2024 Financial Results

06/11/2024 - 22:05

Third Quarter 2024 Total Revenues of $293.8 million, increase of 9% versus prior year Third Quarter 2024 Net Income of $114.8 million, increase of 144% versus prior year Third Quarter 2024 Adjusted EBITDA of $105.3 [...]

Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

06/11/2024 - 22:05

Presented interim data from the ongoing Phase 1 dose escalation study of PRT3789, its first-in-class IV SMARCA2 degrader, demonstrating clinical proof of concept Initiated a Phase 1 trial for PRT7732, its first-in-class [...]

QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024 adjusted EPS outlook

06/11/2024 - 22:05

Q3 2024: Net sales of $502 million (+5% actual rates, +6% constant exchange rates, CER); diluted EPS of $0.44 and adjusted diluted EPS of $0.57 // Net sales of $502 million CER ahead of outlook for at least $495 million [...]

Inari Medical to Participate in the Jefferies London Healthcare Conference

06/11/2024 - 22:05

IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other [...]

Seer Reports Third Quarter 2024 Financial Results

06/11/2024 - 22:05

Growing enthusiasm for Proteograph Product Suite with multiple larger orders from government agencies and continued strong interest in STAC REDWOOD CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: [...]

OrthoPediatrics Corp. Reports Third Quarter 2024 Financial Results and Increases Full Year 2024 Revenue Guidance

06/11/2024 - 22:05

Record Third Quarter 2024 Revenue Increased 37% Year-over-Year WARSAW, Ind., Nov. 06, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on [...]

MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance

06/11/2024 - 22:05

ROCKVILLE, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and [...]

PetMeds® Announces Second Quarter Fiscal 2025 Financial Results

06/11/2024 - 22:05

DELRAY BEACH, Fla., Nov. 06, 2024 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its second quarter ended September 30, 2024 [...]

OraSure Reports Q3 ’24 Revenue of $39.9 Million

06/11/2024 - 22:05

Q3 GAAP EPS of $(0.06) ; Q3 Non-GAAP EPS of $(0.01) OraQuick® HCV Self-test receives initial orders following receipt of WHO pre-qualification status Expanding Sample Management applications into blood proteomics [...]

Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

06/11/2024 - 22:05

Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Inclusion Criteria in the MyPEAK TM -1 Phase 1b/2 Trial of TN-201 Gene Therapy Initial TN-201 Data from Cohort 1 of MyPEAK-1 to be Reported in [...]

Spectral AI Announces 2024 Third Quarter Financial Results

06/11/2024 - 22:05

Revenue Rose to $8.2 Million Company Reaffirms Timeline for Regulatory Submission to U.S. FDA Q3 2024 Overview Research & Development Revenue Rose 138% to $8.2 Million Last Patient Out at Burn Centers for U.S. Burn [...]

Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights

06/11/2024 - 22:05

Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D Plan to initiate 2L pivotal trial of RLY-2608 + [...]

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

06/11/2024 - 22:05

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class [...]

Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates

06/11/2024 - 22:05

- Duchenne: Dosing completed for first three patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected Q1 2025 - - Duchenne: [...]